Mark Miller - Stericycle Executive Chairman
| SRCL Stock | USD 50.33 0.61 1.20% |
Chairman
Mr. Mark C. Miller is no longer as Director of the Stericycle Inc. Effective May 2019. prior to that he was our Executive Chairman since January 2013. Mr. Miller was a director since May 1992. He became our Chief Executive Officer in May 1992 and Chairman of the Board of Directors in August 2008, and served in each of those roles until January 2013. From May 1989 until joining us, Mr. Miller served as vice president for the Pacific, Asia and Africa in the international division of Abbott Laboratories, a diversified health care company, which he joined in 1976 and where he held a number of management and marketing positions since 2018.
| Age | 61 |
| Tenure | 6 years |
| Address | 2355 Waukegan Road, Bannockburn, IL, United States, 60015 |
| Phone | 847 367 5910 |
| Web | https://www.stericycle.com |
Mark Miller Latest Insider Activity
Tracking and analyzing the buying and selling activities of Mark Miller against Stericycle stock is an integral part of due diligence when investing in Stericycle. Mark Miller insider activity provides valuable insight into whether Stericycle is net buyers or sellers over its current business cycle. Note, Stericycle insiders must abide by specific rules, including filing SEC forms every time they buy or sell Stericycle'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Mark Miller over a month ago Acquisition by Mark Miller of 2500 shares of Goosehead Insurance at 73.71 subject to Rule 16b-3 |
Stericycle Management Efficiency
The company has return on total asset (ROA) of 0.0216 % which means that it generated a profit of $0.0216 on every $100 spent on assets. This is way below average. Stericycle's management efficiency ratios could be used to measure how well Stericycle manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to -0.01 this year. The value of Return On Capital Employed is expected to slide to 0.04. At this time, Stericycle's Asset Turnover is quite stable compared to the past year.Similar Executives
| Found 8 records | CHAIRMAN Age | ||
| Mariusz Sikora | Montrose Environmental Grp | N/A | |
| Richard Perlman | Montrose Environmental Grp | 74 | |
| Mariusz Adamowicz | Montrose Environmental Grp | N/A | |
| Piotr Sikora | Montrose Environmental Grp | N/A | |
| Andrew Tan | Montrose Environmental Grp | 66 | |
| James Rutledge | Clean Harbors | 62 | |
| Alan McKim | Clean Harbors | 69 | |
| Stewart Bryan | Montrose Environmental Grp | 75 | |
Management Performance
| Return On Equity | -0.0086 | |||
| Return On Asset | 0.0216 |
Stericycle Leadership Team
Elected by the shareholders, the Stericycle's board of directors comprises two types of representatives: Stericycle inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stericycle. The board's role is to monitor Stericycle's management team and ensure that shareholders' interests are well served. Stericycle's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stericycle's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joel Hackney, Director | ||
| Richard Hoffman, Senior Vice President Chief Accounting Officer | ||
| Brian Anderson, Director | ||
| Kurt Rogers, Executive Vice President General Counsel and Corporate Secretary | ||
| Thomas Brown, Independent Director | ||
| Michael Zafirovski, Independent Director | ||
| Dominic Culotta, Executive Vice President and Chief Engineer | ||
| Cindy Miller, President COO | ||
| John Schetz, Executive Vice President General Counsel | ||
| Janet Zelenka, CFO, Executive Vice President | ||
| John Patience, Independent Director | ||
| Michael Collins, Executive VP and President of Recall and Returns Management Services | ||
| Charles Alutto, CEO and President and Director | ||
| Brenda Frank, Executive Vice President Chief People Officer | ||
| RuthEllen Abdulmassih, Executive Vice President and President Communication & Related Services | ||
| Richard Moore, Executive Vice President - North American Operations | ||
| Michael Weisman, Executive Vice President Chief Ethics and Compliance Officer | ||
| Thomas Chen, Independent Director | ||
| William Seward, Executive Vice President Chief Commercial Officer | ||
| Andrew Ellis, Vice Relations | ||
| Stephen Hooley, Director | ||
| Mark Miller, Executive Chairman | ||
| Kay Priestly, Director | ||
| Cara Simaga, Director Affairs | ||
| Robert Murley, Director | ||
| Cory White, Executive Vice President - Communication and Related Services | ||
| Lynn Bleil, Director | ||
| Rodney Dammeyer, Independent Director | ||
| William Hall, Independent Director | ||
| Joseph Reuter, Executive Vice President Chief People Officer | ||
| David Stahl, Executive Vice President CIO | ||
| Stephen White, Executive Officer | ||
| Daniel Ginnetti, Executive International | ||
| Veronica Hagen, Director | ||
| Brent Arnold, COO and Executive VP | ||
| Jack Schuler, Lead Independent Director |
Stericycle Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stericycle a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0086 | |||
| Return On Asset | 0.0216 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 6.41 B | |||
| Shares Outstanding | 92.78 M | |||
| Shares Owned By Insiders | 0.35 % | |||
| Shares Owned By Institutions | 99.65 % | |||
| Number Of Shares Shorted | 2.08 M | |||
| Price To Earning | 726.43 X |
Currently Active Assets on Macroaxis
When determining whether Stericycle is a strong investment it is important to analyze Stericycle's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Stericycle's future performance. For an informed investment choice regarding Stericycle Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stericycle. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Stericycle Stock please use our How to buy in Stericycle Stock guide.Note that the Stericycle information on this page should be used as a complementary analysis to other Stericycle's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Stericycle Stock analysis
When running Stericycle's price analysis, check to measure Stericycle's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Stericycle is operating at the current time. Most of Stericycle's value examination focuses on studying past and present price action to predict the probability of Stericycle's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Stericycle's price. Additionally, you may evaluate how the addition of Stericycle to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is Stericycle's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stericycle. If investors know Stericycle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stericycle listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.54) | Earnings Share (0.23) | Revenue Per Share 28.78 | Quarterly Revenue Growth (0.03) | Return On Assets 0.0216 |
The market value of Stericycle is measured differently than its book value, which is the value of Stericycle that is recorded on the company's balance sheet. Investors also form their own opinion of Stericycle's value that differs from its market value or its book value, called intrinsic value, which is Stericycle's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stericycle's market value can be influenced by many factors that don't directly affect Stericycle's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stericycle's value and its price as these two are different measures arrived at by different means. Investors typically determine if Stericycle is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stericycle's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.